Literature DB >> 24752393

Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.

Sarantis Livadas1, Christos Pappas, Athanasios Karachalios, Evangelos Marinakis, Nikoleta Tolia, Maria Drakou, Philippos Kaldrymides, Dimitrios Panidis, Evanthia Diamanti-Kandarakis.   

Abstract

Hyperandrogenemia modifies phenotypic characteristics of women with polycystic ovary syndrome (PCOS). The aim of the present study is to evaluate (a) the prevalence of hyperandrogenemia in PCOS women (Rotterdam criteria) and (b) the impact of either the degree or the type of hyperandrogenemia on phenotype. Anthropometric, clinical, hormonal, metabolic and ultrasound characteristics of 1,218 women with PCOS were analyzed in this cross-sectional study. The prevalence of hyperandrogenemia was 58.8 %. Women with hyperandrogenemia had higher luteinizing hormone (LH), follicle-stimulating hormone (FSH), free androgen index, lower sex-hormone-binding globulin (SHBG) and fasting glucose levels compared to women with normal androgens (p < 0.001 for all comparisons; p = 0.001 for fasting glucose). Regarding the presence of isolated hyperandrogenemia, the group with only elevated testosterone levels was termed GT and an analogous categorization was made for dehydroepiandrosterone sulfate (GD) and androstenedione (Δ4) (GΔ4), respectively. GT, GD and GΔ4 comprised the 17.2, 7.6 and 4.1 % of total cohort, respectively. These groups differed significantly between them in LH, LH/FSH ratio, and SHBG (p < 0.001). Hyperandrogenemia is found in almost 60 % of women with PCOS (Rotterdam criteria), and it affects hormonal characteristics of these women such as LH and SHBG values. Regarding the impact of isolated hyperandrogenemia on PCOS characteristics, it appears that Δ4 and testosterone elevations are associated with increased LH levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752393     DOI: 10.1007/s12020-014-0200-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  30 in total

1.  Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries.

Authors:  A J Jakimiuk; S R Weitsman; A Navab; D A Magoffin
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

Review 2.  Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.

Authors:  Robert L Rosenfield; Brian Bordini
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

3.  Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome.

Authors:  Nermin Köşüş; Aydın Köşüş; Zeynep Kamalak; Deniz Hızlı; Nilgün Ö Turhan
Journal:  Gynecol Endocrinol       Date:  2012-02-01       Impact factor: 2.260

4.  Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries.

Authors:  V L Nelson; R S Legro; J F Strauss; J M McAllister
Journal:  Mol Endocrinol       Date:  1999-06

5.  Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome.

Authors:  Frank González; Chang Ling Sia; Frank Z Stanczyk; Hilary E Blair; Michelle E Krupa
Journal:  Endocrine       Date:  2012-07-01       Impact factor: 3.633

Review 6.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

Review 7.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

8.  Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome.

Authors:  A A Kyei-Mensah; S LinTan; J Zaidi; H S Jacobs
Journal:  Hum Reprod       Date:  1998-06       Impact factor: 6.918

Review 9.  Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.

Authors:  Evanthia Diamanti-Kandarakis
Journal:  Expert Rev Mol Med       Date:  2008-01-30       Impact factor: 5.600

Review 10.  Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation.

Authors:  V Toscano; R Balducci; P Bianchi; R Guglielmi; A Mangiantini; F Sciarra
Journal:  J Steroid Biochem Mol Biol       Date:  1992-10       Impact factor: 4.292

View more
  20 in total

1.  Ovarian Androgens Maintain High GnRH Neuron Firing Rate in Adult Prenatally-Androgenized Female Mice.

Authors:  Eden A Dulka; Laura L Burger; Suzanne M Moenter
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

2.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

3.  Hyperandrogenism induces proportional changes in the expression of Kiss-1, Tac2, and DynA in hypothalamic KNDy neurons.

Authors:  Hiroe Okada; Haruhiko Kanasaki; Tuvshintugs Tumurbaatar; Zolzaya Tumurgan; Aki Oride; Satoru Kyo
Journal:  Reprod Biol Endocrinol       Date:  2022-06-21       Impact factor: 4.982

4.  ANTIMÜLLERIAN HORMONE AS INDICATOR OF OVARIAN DYSFUNCTION.

Authors:  A Bothou; N Koutlaki; G Iatrakis; G Mastorakos; P Tsikouras; V Liberis; G Galazios; A Liberis; A Lykeridou; S Zervoudis
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

5.  The Effect of Ageing on Clinical, Hormonal and Sonographic Features Associated with PCOS-A Long-Term Follow-Up Study.

Authors:  Małgorzata Jacewicz-Święcka; Sławomir Wołczyński; Irina Kowalska
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

6.  Pathogenesis of Reproductive and Metabolic PCOS Traits in a Mouse Model.

Authors:  Valentina Rodriguez Paris; Melissa C Edwards; Ali Aflatounian; Michael J Bertoldo; William L Ledger; David J Handelsman; Robert B Gilchrist; Kirsty A Walters
Journal:  J Endocr Soc       Date:  2021-04-07

7.  Constitutive expression of Steroidogenic factor-1 (NR5A1) disrupts ovarian functions, fertility, and metabolic homeostasis in female mice.

Authors:  Emmi Rotgers; Barbara Nicol; Karina Rodriguez; Saniya Rattan; Jodi A Flaws; Humphrey Hung-Chang Yao
Journal:  FASEB J       Date:  2021-08       Impact factor: 5.834

8.  Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden.

Authors:  K Kosidou; C Dalman; L Widman; S Arver; B K Lee; C Magnusson; R M Gardner
Journal:  Mol Psychiatry       Date:  2015-12-08       Impact factor: 15.992

Review 9.  Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis.

Authors:  Rui Yang; Shuo Yang; Rong Li; Ping Liu; Jie Qiao; Yanwu Zhang
Journal:  Reprod Biol Endocrinol       Date:  2016-10-18       Impact factor: 5.211

10.  The relationships of sex hormone-binding globulin, total testosterone, androstenedione and free testosterone with metabolic and reproductive features of polycystic ovary syndrome.

Authors:  Pomme I H G Simons; Olivier Valkenburg; Judith A P Bons; Coen D A Stehouwer; Martijn C G J Brouwers
Journal:  Endocrinol Diabetes Metab       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.